Expectations and Prior Experiences Associated With Adverse Effects of COVID-19 Vaccination.

Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE

Original Publication: Chicago, IL : American Medical Association, [2018]-

COVID-19*/prevention & control ; COVID-19 Vaccines*/adverse effects ; Drug-Related Side Effects and Adverse Reactions*; Adult ; Female ; Humans ; Male ; 2019-nCoV Vaccine mRNA-1273 ; BNT162 Vaccine ; Cohort Studies ; Motivation ; Prospective Studies ; Vaccination/adverse effects

Importance: Uptake of vaccination against COVID-19 is strongly affected by concerns about adverse effects. Research on nocebo effects suggests that these concerns can amplify symptom burden.
Objective: To investigate whether positive and negative expectations prior to COVID-19 vaccination are associated with systemic adverse effects.
Design, Setting, and Participants: This prospective cohort study analyzed the association of expected benefits and risks of vaccination, adverse effects at first vaccination, and observed adverse effects in close contacts with severity of systemic adverse effects among adults receiving a second dose of messenger RNA (mRNA)-based vaccines between August 16 and 28, 2021. A total of 7771 individuals receiving the second dose at a state vaccination center in Hamburg, Germany, were invited to participate; of these, 5370 did not respond, 535 provided incomplete information, and 188 were excluded retrospectively. The mobile application m-Path was used for data collection.
Main Outcomes and Measures: Primary outcome was a composite severity index of systemic adverse effects in 12 symptom areas measured once daily with an electronic symptom diary over 7 consecutive days. Data were analyzed by mixed-effects multivariable ordered logistic regression adjusted for prevaccine symptom levels and observation times.
Results: A total of 10 447 observations from 1678 individuals receiving vaccinations (BNT162b2 [Pfizer BioNTech] in 1297 [77.3%] and mRNA-1273 [Moderna] in 381 [22.7%]) were collected. The participants' median age was 34 (IQR, 27-44) years, and 862 (51.4%) were women. The risk for more severe adverse effects was higher for persons expecting a lower benefit of vaccination (odds ratio [OR] for higher expectations, 0.72 [95% CI, 0.63-0.83]; P < .001), expecting higher adverse effects of vaccination (OR, 1.39 [95% CI, 1.23-1.58]; P < .001), having experienced higher symptom burden at the first vaccination (OR, 1.60 [95% CI, 1.42-1.82]; P < .001), scoring higher on the Somatosensory Amplification Scale (OR, 1.21 [95% CI, 1.06-1.38]; P = .004), and if the vaccine mRNA-1273 was given rather than BNT162b2 (OR, 2.45 [95% CI, 2.01-2.99]; P < .001). No associations were seen for observed experiences.
Conclusions and Relevance: In this cohort study, several nocebo effects occurred in the first week after COVID-19 vaccination. The severity of systemic adverse effects was associated not only with vaccine-specific reactogenicity but also more negative prior experiences with adverse effects from the first COVID-19 vaccination, more negative expectations regarding vaccination, and tendency to catastrophize instead of normalize benign bodily sensations. Clinician-patient interactions and public vaccine campaigns may both benefit from these insights by optimizing and contextualizing information provided about COVID-19 vaccines.

Health Psychol. 2016 Dec;35(12):1334-1355. (PMID: 27657801)
Ann Oncol. 2016 Oct;27(10):1909-15. (PMID: 27551051)
JAMA Health Forum. 2021 Apr 1;2(4):e210804. (PMID: 36218819)
Front Psychiatry. 2021 Apr 27;12:587122. (PMID: 33986697)
Orthopade. 2012 Apr;41(4):303-10. (PMID: 22476421)
Ann Behav Med. 2019 Mar 1;53(3):267-282. (PMID: 29868792)
N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609)
J Multidiscip Healthc. 2016 May 04;9:211-7. (PMID: 27217764)
Postgrad Med J. 2022 Oct 1;98(1164):756-764. (PMID: 37062994)
JAMA. 2002 Feb 6;287(5):622-7. (PMID: 11829702)
Lancet Reg Health Eur. 2022 Jan;12:100253. (PMID: 34729549)
Ann Epidemiol. 2003 Feb;13(2):105-10. (PMID: 12559669)
Eur J Epidemiol. 2001;17(11):991-9. (PMID: 12380710)
Arthritis Care Res (Hoboken). 2010 Jun;62(6):791-9. (PMID: 20191574)
Health Psychol. 2015 Oct;34(10):1033-1037. (PMID: 25689300)
BMC Med. 2017 Jan 10;15(1):4. (PMID: 28069021)
Nat Med. 2021 Aug;27(8):1385-1394. (PMID: 34272499)
JAMA Netw Open. 2022 Jan 4;5(1):e2143955. (PMID: 35040967)
JAMA. 2021 Jun 1;325(21):2201-2202. (PMID: 33818592)
J Psychosom Res. 1996 Jan;40(1):95-104. (PMID: 8730649)
BMJ. 2012 Mar 23;344:e1756. (PMID: 22446569)
Psychosomatics. 2009 Nov-Dec;50(6):613-21. (PMID: 19996233)
Ann Behav Med. 2022 Aug 2;56(8):761-768. (PMID: 35640203)
Vaccine. 2021 Apr 8;39(15):2024-2034. (PMID: 33722411)
Psychother Psychosom. 2022;91(2):136-138. (PMID: 34736267)
Int J Environ Res Public Health. 2021 Jul 29;18(15):. (PMID: 34360345)
BMJ. 2022 May 18;377:e069676. (PMID: 35584816)
Clin Psychol Eur. 2020 Mar 31;2(1):e2695. (PMID: 36397978)
Ann Behav Med. 2019 Jun 4;53(7):621-629. (PMID: 30204841)
Mayo Clin Proc. 2021 Mar;96(3):699-707. (PMID: 33673921)
Am J Bioeth. 2012;12(3):22-9. (PMID: 22416745)
J Psychosom Res. 2015 Dec;79(6):492-7. (PMID: 26553385)
J Affect Disord. 2010 Apr;122(1-2):86-95. (PMID: 19616305)
J Health Econ. 2014 May;35:34-46. (PMID: 24595066)
N Engl J Med. 2020 Feb 6;382(6):554-561. (PMID: 32023375)
PLoS One. 2014 Sep 15;9(9):e107665. (PMID: 25222607)
Pharmacol Rev. 2015 Jul;67(3):697-730. (PMID: 26126649)
Front Public Health. 2022 Aug 26;10:873596. (PMID: 36091533)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
Front Psychiatry. 2019 Jul 25;10:504. (PMID: 31427995)

EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273)
0 (BNT162 Vaccine)
0 (COVID-19 Vaccines)

Date Created: 20230327 Date Completed: 20230329 Latest Revision: 20230721

20240628

PMC10043751

10.1001/jamanetworkopen.2023.4732

36972051